The Perirenal Fat Thickness Was Associated with Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus

Overview

Journal Diabetes Metab Syndr Obes

Publisher Dove Medical Press

Specialty Endocrinology

Date 2022 May 19

PMID 35586202

Authors

Yuxian Yang

Shuting Li

Yuechao Xu

Jing Ke

Dong Zhao

Affiliations

Soon will be listed here.

Abstract

Purpose: Obesity is an important risk factor for nonalcoholic fatty liver disease (NAFLD). Perirenal fat and paranephric fat were seldom studied in NAFLD. We aimed to explore the relationship between perirenal fat thickness (PrFT) and paranephric fat thickness (PnFT) and NAFLD in patients with type 2 diabetes mellitus (T2DM).

Patients And Methods: A total of 493 diabetic patients including 231 NAFLD patients were enrolled in our study from September 2019 to December 2020. Patients with NAFLD were categorized into three subgroups according to the severity and fibrosis risk of NAFLD. Anthropometric indices and clinical characteristics were collected from clinical records. PrFT and PnFT were measured via ultrasound. Multivariate logistic regression analysis was used to assess the association between PrFT, PnFT and presence, severity and advanced fibrosis risk of NAFLD.

Results: Compared with non-NAFLD patients, those with NAFLD had significantly higher PrFT and PnFT. The PrFT and PnFT were independently associated with presence of NAFLD and the PrFT was independently associated with the advanced fibrosis risk of NAFLD after adjusting confounding factors.

Conclusion: The PrFT was independently associated with the presence and advanced fibrosis risk of NAFLD in patients with T2DM.

Citing Articles

The association of perirenal adipose tissue accumulation with left ventricular hypertrophy and the mediating role of insulin resistance: a cross-sectional study involving 1112 individuals with type 2 diabetes mellitus.

Wang W, Chen Y, Qiu X, Guo X Front Endocrinol (Lausanne). 2025; 15():1465577.

PMID: 39850485 PMC: 11754053. DOI: 10.3389/fendo.2024.1465577.

The Interplay of Systemic Inflammation and Oxidative Stress in Connecting Perirenal Adipose Tissue to Hyperuricemia in Type 2 Diabetes Mellitus: A Mediation Analysis.

Wang W, Tu M, Qiu X, Tong Y, Guo X J Inflamm Res. 2024; 17:11319-11329.

PMID: 39720699 PMC: 11668320. DOI: 10.2147/JIR.S488964.

Perirenal fat thickness is an independent predictor for metabolic syndrome in steatotic liver disease.

Choi J, Lee C, Kang B, Kim M Sci Rep. 2024; 14(1):26548.

PMID: 39489811 PMC: 11532468. DOI: 10.1038/s41598-024-77512-5.

Assessing the Prognostic Utility of the New Mayo Adhesive Probability Score in East Asian Populations and its Correlation with Metabolic-Associated Fatty Liver Disease.

Yi Y, Ma Z, Lin C, Yu F, Dong X, Chen Q Physiol Res. 2024; 73(3):393-403.

PMID: 39027956 PMC: 11299780. DOI: 10.33549/physiolres.935297.

References

Lee C, Kim J, Jung Y . Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Cells. 2019; 8(10). PMC: 6835656. DOI: 10.3390/cells8101259. View

Stefan N, Haring H, Cusi K . Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2018; 7(4):313-324. DOI: 10.1016/S2213-8587(18)30154-2. View

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6):1388-402. DOI: 10.1016/j.jhep.2015.11.004. View

Kim D, Kim W, Joo S, Kim J, Harrison S, Younossi Z . Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease. Liver Int. 2018; 39(2):332-341. DOI: 10.1111/liv.13983. View

Lu Z, Shao Z, Li Y, Wulasihan M, Chen X . Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study. World J Gastroenterol. 2016; 22(13):3663-9. PMC: 4814652. DOI: 10.3748/wjg.v22.i13.3663. View

Sookoian S, Pirola C . Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2017; 47(1):16-25. DOI: 10.1111/apt.14401. View

Milic S, Lulic D, Stimac D . Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014; 20(28):9330-7. PMC: 4110564. DOI: 10.3748/wjg.v20.i28.9330. View

Huh J, Kim K, Kim S, Han S, Han K, Cha B . Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. Metabolism. 2016; 66:23-31. DOI: 10.1016/j.metabol.2016.10.003. View

10.

du Plessis J, van Pelt J, Korf H, Mathieu C, Van der Schueren B, Lannoo M . Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015; 149(3):635-48.e14. DOI: 10.1053/j.gastro.2015.05.044. View

11.

Chiyanika C, Wong V, Wong G, Chan H, Hui S, Yeung D . Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study. Clin Transl Gastroenterol. 2021; 12(2):e00300. PMC: 7889374. DOI: 10.14309/ctg.0000000000000300. View

12.

Lin Y, Chang P, Liu K, Chang M, Ni Y . Predictors for incidence and remission of nonalcoholic fatty liver disease in obese children and adolescents. J Formos Med Assoc. 2021; 121(1 Pt 1):36-42. DOI: 10.1016/j.jfma.2021.01.004. View

13.

Polyzos S, Kountouras J, Mantzoros C . Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2018; 92:82-97. DOI: 10.1016/j.metabol.2018.11.014. View

14.

Bril F, Cusi K . Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Diabetes Care. 2017; 40(3):419-430. DOI: 10.2337/dc16-1787. View

15.

Hui J, Sud A, Farrell G, Bandara P, Byth K, Kench J . Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology. 2004; 125(6):1695-704. DOI: 10.1053/j.gastro.2003.08.032. View

16.

Jung C, Rhee E, Kwon H, Chang Y, Ryu S, Lee W . Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis. Endocrinol Metab (Seoul). 2020; 35(1):165-176. PMC: 7090310. DOI: 10.3803/EnM.2020.35.1.165. View

17.

Kechagias S, Nasr P, Blomdahl J, Ekstedt M . Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism. 2020; 111S:154183. DOI: 10.1016/j.metabol.2020.154183. View

18.

Shao C, Ye J, Li F, Feng S, Wang W, Zhong B . Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease. Dig Liver Dis. 2019; 51(10):1392-1399. DOI: 10.1016/j.dld.2019.02.019. View

19.

Mantovani A, Byrne C, Bonora E, Targher G . Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. Diabetes Care. 2018; 41(2):372-382. DOI: 10.2337/dc17-1902. View

20.

Kawasaki S, Hasegawa O, Satoh S, Numata K, Terauchi Y . Sonographic assessment of fatty liver infiltration using the measurement of para- and perirenal fat thickness. J Clin Ultrasound. 2010; 38(9):470-4. DOI: 10.1002/jcu.20736. View